Vollmer K O, Poisson A
Arzneimittelforschung. 1976;26(10):1827-36.
Absorption, distribution, metabolism and excretion of the potent analgesic ethyl-DL-trans-2-timethylamino-1-phenyl-chclohex-3-ene-trans-1-carboxylate-hydrochloride (tilidine-HCl, Gö 1261 C, active ingredient of Vloron) were investigated in rats and dogs, using the radioactively labelled substance. Following oral administration, tilidine-HCl is rapidly and completely absorbed from the duodenum. During absorption, tilidine undergoes a marked first-pass effect. In plasma several metabolites are found, part of them occurring in higher concentrations than the unchanged substance. The metabolites are also formed rapidly after parenteral administration, unchanged tilidine being found in higher concentrations than any of the metabolites at all times measured. Following both routes of administration, the Met. I (nortilidine), also possessing a strong analgesic activity, reaches similar plasma levels. 14C distribution studies in rats showed a relatively high concentration of the radioactivity in the excretory organs, liver and kidneys. In brain, muscle tissue and blood much lower 14C concentrations are found. The concentrations measured in the foetal organs correspond to those in the muscle tissue of the mother animals and are, therefore, much lower than in most maternal organs. The radioactivity is eliminated from the foetal organs at the same rate as from the maternal organs. Tilidine is rapidly and completely eliminated with the excrements, nearly exclusively in the form of metabolic products. Rats eliminate 50% of the given radioactivity via the kidneys. The relatively high fecal elimination is based on the biliary metabolites. Following intraduodenal and intravenous administration to rats with an interrupted enterohepatic circulation, about 80% of the dose is eliminated with bile. The biliary metabolites are partly reabsorbed. In dogs, approx. 80% of the applied radioactivity is eliminated with urine.
使用放射性标记物质,对强效镇痛药盐酸乙基-DL-反式-2-二甲基氨基-1-苯基-环己-3-烯-反式-1-羧酸酯(替利定盐酸盐,Gö 1261 C,Vloron的活性成分)在大鼠和犬体内的吸收、分布、代谢及排泄情况进行了研究。口服给药后,盐酸替利定从十二指肠迅速且完全吸收。吸收过程中,替利定经历显著的首过效应。血浆中可发现多种代谢产物,部分代谢产物的浓度高于未变化的母体物质。非肠道给药后代谢产物也迅速形成,在所有测定时间内,未变化的替利定浓度均高于任何一种代谢产物。两种给药途径后,同样具有强镇痛活性的代谢物I(去甲替利定)达到相似的血浆水平。大鼠体内的¹⁴C分布研究表明,排泄器官、肝脏和肾脏中的放射性浓度相对较高。在脑、肌肉组织和血液中,¹⁴C浓度低得多。胎儿器官中测得的浓度与母体动物肌肉组织中的浓度相当,因此远低于大多数母体器官中的浓度。胎儿器官中的放射性以与母体器官相同的速率消除。替利定迅速且完全随粪便排出,几乎完全以代谢产物的形式排出。大鼠通过肾脏排出50%的给予放射性。较高的粪便排泄率基于胆汁中的代谢产物。对肠肝循环中断的大鼠进行十二指肠内和静脉内给药后,约80%的剂量随胆汁排出。胆汁中的代谢产物部分被重吸收。在犬体内,约80%的给予放射性随尿液排出。